Navigation Links
Abaxis Reports Record Financial Performance for the First Quarter of Fiscal 2010

UNION CITY, Calif., July 30 /PRNewswire-FirstCall/ -- ABAXIS, Inc. (Nasdaq: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today reported financial results for the first fiscal quarter ended June 30, 2009.

Record quarterly highlights include:

  • Revenues of $29.6 million, up 21% over last year's comparable quarter.
  • Veterinary market sales of $21.8 million, up 31% over last year's comparable quarter.
  • North America revenues of $24.1 million, up 19% over last year's comparable quarter.
  • International revenues of $5.5 million, up 29% over last year's comparable quarter.
  • Medical and veterinary reagent disc sales of $18.4 million, up 31% over last year's comparable quarter.
  • Gross profit of $17.2 million, up 27% over last year's comparable quarter.
  • Operating income of $5.7 million, up 42% over last year's comparable quarter.
  • Net income of $3.8 million, up 35% over last year's comparable quarter.

Quarterly Results: For the fiscal quarter ended June 30, 2009, Abaxis reported revenues of $29.6 million, as compared with revenues of $24.6 million for the comparable period last year, an increase of 21 percent. Revenues from instrument sales, which include chemistry analyzers, hematology instruments and coagulation analyzers, decreased by an aggregate of $1.5 million, or 20 percent, over the same period last year. Revenues from consumables, which include reagent discs, hematology reagent kits, coagulation cartridges, i-STAT cartridges and heartworm rapid tests, increased by an aggregate of $6.0 million, or 40 percent, over the same period last year. The company reported net income of $3.8 million, compared to $2.8 million for the same period last year. The company's effective tax rate in the quarter ended June 30, 2009 was 40 percent, compared to 38 percent for the same period last year. The company reported diluted net income per share of $0.17 (calculated based on 22,357,000 shares) for the first quarter of fiscal 2010, compared to $0.12 per share (calculated based on 22,398,000 shares) for the same period last year.

Other Reported Information: Consumables revenues for the first quarter of fiscal 2010 was $20.9 million, up 40 percent over the $14.9 million reported for the same period last year. Total sales in the medical market for the first quarter of fiscal 2010 were $5.8 million, a decrease of 12 percent over last year's comparable quarter. Medical sales in North America, excluding sales to the U.S. government, during the first quarter of fiscal 2010 were $3.7 million, a decrease of 16 percent over last year's comparable quarter. Total sales in the veterinary market for the first quarter of fiscal 2010 were $21.8 million, up 31 percent over last year's comparable quarter. Veterinary reagent disc sales for the first quarter of fiscal 2010 were $14.5 million, an increase of 40 percent compared to the same period last year.

The company ended the first quarter with an aggregate of $80.8 million in cash, cash equivalents and investments. As of June 30, 2009, the company held a total of $20.2 million in short-term investments and $13.8 million in long-term investments.

Clint Severson, chairman and chief executive officer of Abaxis, commented, "This was a very strong quarter for Abaxis. We achieved substantial revenue and net income growth, strong diagnostic reagent disc sales increases and continued improvement in our cash position and liquidity. But more importantly, we are gaining real traction in the acceptance of new products that will contribute to our top-line and bottom-line for years to come. For example, our new VetScan VSpro Coagulation Analyzer got off to a strong start in its initial roll-out with unit sales representing 12.5% of our total instrument sales in the first quarter. Our new VetScan Canine Heartworm Rapid Test continues to be received very well by the veterinary community and our distribution agreement with Abbott's Point-of-Care business started in earnest during the quarter with the shipment of i-STAT cartridges. We expect these products and business relationships will grow and thrive in the coming years."

Mr. Severson continued, "During the very challenging economic environment of the past couple of years Abaxis has taken the opportunity to better position the company for the years ahead. We have been successful in improving the financial underpinnings of the company by conservatively managing and growing our cash position, avoiding taking on debt and achieving operating efficiencies that will meaningfully contribute to our financial results going forward. Additionally, we have made significant improvements in product engineering, hardware, and software that translate into leading-edge point-of-care technology in both the medical and veterinary markets. With a strong focus on the future we are successfully moving Abaxis through a very traumatic economic period in a position to prosper as we move into the next market cycle."

Conference Call

Abaxis has scheduled a conference call to discuss its results at 4:15 p.m. Eastern Time on July 30, 2009. Participants can dial (800) 860-2442 or (412) 858-4600 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the company's website at A replay of the call is available by visiting for the next 30 days or by calling (877) 344-7529 or (412) 317-0088, access code 432270, through August 3, 2009. This press release is also available prior to and after the call via Abaxis' website or the Securities and Exchange Commission's website at

About Abaxis

Abaxis develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.

Use of Non-GAAP Financial Measures

To supplement its financial statements presented in accordance with United States generally accepted accounting principles (GAAP), Abaxis uses operating income per share. This non-GAAP financial presentation is not a measurement of performance under GAAP in the United States of America. Management uses this measure in comparing Abaxis' operating results with historical performance and believes it provides meaningful and comparable information to management and investors to assist in their review of Abaxis' performance relative to prior periods and its competitors.

This press release includes, and our conference call will include, statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not limited to statements related to Abaxis' cash position, financial resources and potential for future growth, market acceptance of new or planned product offerings, process improvements and product manufacturing quality and efficiencies in future production of our products. Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," "anticipates," or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this press release or in Abaxis' conference call may be affected by risks and uncertainties, including, but not limited to, those related to the market acceptance of the company's products and the continuing development of its products, required United States Food and Drug Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with entering the human diagnostic market on a larger scale, risks related to the protection of the company's intellectual property or claims of infringement of intellectual property asserted by third parties, risks related to condition of the United States economy, risks involved in carrying of inventory and other risks detailed under "Risk Factors" in Abaxis' Annual Report on Form 10-K for the fiscal year ended March 31, 2009 and Abaxis' other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.

Financial Tables on Following Pages

    Condensed Consolidated Statements of Operations
    (In thousands, except per share data)

                                                           Three Months Ended
                                                                 June 30,
                                                             2009       2008
                                                             ----       ----

    Revenues                                               $29,625    $24,572
    Cost of revenues                                        12,470     11,069
                                                            ------     ------
    Gross profit                                            17,155     13,503
                                                            ------     ------

    Operating expenses:
         Research and development                            2,573      1,997
         Sales and marketing                                 6,360      5,827
         General and administrative                          2,498      1,662
                                                             -----      -----
    Total operating expenses                                11,431      9,486
                                                            ------      -----

    Income from operations                                   5,724      4,017
    Interest and other income (expense), net                   514        462
                                                               ---        ---
    Income before income tax provision                       6,238      4,479
    Income tax provision                                     2,482      1,703
                                                             -----      -----
    Net income                                              $3,756     $2,776
                                                            ======     ======

    Net income per share:
      Basic net income per share                             $0.17      $0.13
                                                             =====      =====
      Diluted net income per share                           $0.17      $0.12
                                                             =====      =====

    Shares used in the calculation of net income per share:
      Weighted average common shares outstanding - basic    21,965     21,735
      Weighted average common shares outstanding - diluted  22,357     22,398

    Condensed Consolidated Balance Sheets
    (Unaudited and in thousands)

                                                       June 30,    March 31,
                                                        2009         2009
                                                        ----         ----
    Current assets:
      Cash and cash equivalents                       $46,868      $49,237
      Short-term investments                           20,215       20,776
      Accounts receivables, net                        24,159       21,983
      Inventories                                      15,488       15,735
      Prepaid expenses                                    959          957
      Net deferred tax asset, current                   4,628        4,676
                                                        -----        -----
        Total current assets                          112,317      113,364
      Long-term investments                            13,759        4,886
      Property and equipment, net                      14,366       14,798
      Intangible assets, net                            5,031        5,175
      Other assets                                         35           24
      Net deferred tax asset, non-current               2,464        2,464
                                                        -----        -----
        Total assets                                 $147,972     $140,711
                                                     ========     ========

    Current liabilities:
      Accounts payable                                 $4,303       $3,963
      Accrued payroll and related expenses              4,296        3,698
      Accrued taxes                                     2,005           34
      Other accrued liabilities                         1,135        1,116
      Deferred revenue                                  1,047        1,024
      Warranty reserve                                  1,732        1,714
                                                        -----        -----
        Total current liabilities                      14,518       11,549
                                                       ------       ------

    Non-current liabilities:
      Deferred rent                                        92          137
      Deferred revenue                                  1,429        1,550
      Warranty reserve                                    653          583
                                                          ---          ---
        Total non-current liabilities                   2,174        2,270
                                                        -----        -----

    Shareholders' equity:
      Common stock                                    118,489      117,846
      Retained earnings                                12,802        9,046
      Accumulated other comprehensive loss                (11)           -
                                                          ---          ---
        Total shareholders' equity                    131,280      126,892
                                                      -------      -------
        Total liabilities and shareholders' equity   $147,972     $140,711
                                                     ========     ========

    Non-GAAP Operating Income Per Share
    (In thousands, except per share data)

                                                               Three Months
                                                                 June 30,
                                                              2009      2008
                                                              ----      ----
    Shares used in the calculation of operating income Per
     share (non-GAAP):
      Weighted average common shares outstanding - basic     21,965    21,735
      Weighted average common shares outstanding - diluted   22,357    22,398

    Non-GAAP operating income per share - basic               $0.26     $0.18
                                                              =====     =====
    Non-GAAP operating income per share - diluted             $0.26     $0.18
                                                              =====     =====

    Revenues by Geographic Region
    (In thousands)

                                                     Three Months
                                                       June 30,
                                                    2009      2008
                                                    ----      ----
    North America                                 $24,111   $20,295
    International                                   5,514     4,277
                                                    -----     -----
    Total revenues                                $29,625   $24,572
                                                  =======   =======

    Revenues by Customer Group
    (In thousands)

                                                     Three Months Ended
                                                          June 30,
                                                      2009        2008
                                                      ----        ----
    Medical Market                                  $5,763      $6,529
    Veterinary Market                               21,823      16,613
    Other                                            2,039       1,430
                                                     -----       -----
    Total revenues                                 $29,625     $24,572
                                                   =======     =======


SOURCE Abaxis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Abaxis to Report First Quarter Fiscal 2010 Financial Results Thursday, July 30, 2009
2. Abaxis, Inc. to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
3. Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2009
4. Abaxis to Report Fourth Quarter Fiscal 2009 Financial Results Wednesday, April 29, 2009
5. ABAXIS Realigns North American Medical Sales and Marketing
6. Abaxis, Inc. to Attend Lazard Capital Markets Medical Technologies Conference
7. Abaxis, Inc. to Present at Sidoti & Companys Thirteenth Annual New York Emerging Growth Institutional Investor Forum
8. Abaxis Reports Financial Performance for the Third Quarter of Fiscal 2009
9. ABAXIS Announces Launch of Two New Products at the NAVC
10. ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd.
11. Abaxis, Inc. to Present at Sidoti & Companys Sixth Annual Palm Beach Emerging Growth Institutional Investor Forum
Post Your Comments:
(Date:11/27/2015)... ... 2015 , ... Consistent with the Radiology Business Management ... Radiology Marketing Programs meeting will showcase some of the best 2015 radiology ... Palace in Las Vegas with a pre-conference session on a collaborative approach for ...
(Date:11/27/2015)... Minn. (PRWEB) , ... November 27, 2015 , ... ... start failing. Secura Consultants has prided itself for not only fulfilling the needs ... income protection solutions at an affordable price and providing top-tier customer service. However, ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... largest, most successful and prominent nonprofit healthcare organizations in the country. They have ... with various organizations, and helped advance the healthcare industry as a whole through ...
(Date:11/27/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class ... (Long Term Support) into its Q-Suite 5.10 product line. , Making the change ... version of Asterisk that will receive not only security fixes, but feature and ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD ... for diagnostic imaging in the Waterloo region. Using the Ocean Platform, family physicians ... directly from their electronic medical record (EMR) without the need for redundant patient ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015 On Tuesday, ... federal bellwether trial against Wright Medical Technology, Inc. ... their Conserve metal-on-metal hip implant device, awarded $11 ... a two week trial and three days of ... hip device was defectively designed and unreasonably dangerous, ...
(Date:11/25/2015)... Nov. 25, 2015  Henry Schein, Inc., the world,s ... office-based dental, medical and animal health practitioners, will unveil ... Henry Schein ConnectDental® Pavilion , which brings together ... open solutions designed to help any practice or laboratory ... for a schedule of experts appearing at the ...
(Date:11/25/2015)... 2015 Allergan plc (NYSE: AGN ) today ... New York State Attorney General,s Office to ... and other statutes with the Attorney General over the decision ... marketing and selling the now generic version of memantine immediate ... liability, has released its counterclaims against New York ...
Breaking Medicine Technology: